Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 56 clinical trials
featured
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL), Lymphoplasmacytic Lymphoma(LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma(SMZL)

(MBL), chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). Applying these

cancer
lymphadenopathy
waldenstrom's macroglobulinemia
lymphoma
marginal zone lymphoma
  • 88 views
  • 15 Apr, 2019
  • 1 location
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.

chronic lymphocytic leukemia refractory
measurable disease
renal function tests
blood transfusion
renal function
  • 92 views
  • 13 Dec, 2020
  • 29 locations
An Open-label Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage 1) and a dose expansion stage (Stage 2).

  • 0 views
  • 23 Jan, 2021
  • 10 locations
Dasatinib In Waldenstr m Macroglobulinemia

This is Phase I pilot, single center study designed to explore the safety of Dasatinib in symptomatic Waldenstrm Macroglobulinemia participants who are progressing on ibrutinib therapy with BTK

measurable disease
lymphadenopathy
monoclonal protein
igm level
potassium
  • 2 views
  • 30 Dec, 2020
A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia

Hypothesis; That inhibition of plasma Blys by the monoclonal antibody Belimumab will reduce both the survival of the lymphoplasmacytoid cells of Waldenstrom Macroglobulinaemia (WM), and

  • 8 views
  • 08 Nov, 2020
  • 1 location
R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia

A multicenter prospective phase II study of rituximab combined, lenalidomide, dexamethasone followed by lenalidomide maintenance in patients with newly diagnosed Waldenstrm's macroglobulinemia

bortezomib
measurable disease
lenalidomide
dexamethasone
rituximab
  • 0 views
  • 01 Oct, 2020
  • 1 location
Zanubrutinib Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

This study aims to evaluate the efficacy of BTK inhibitor Zanubrutinib combined with Ixazomib and Dexamethasone (ZID) for the newly diagnosed Waldenstrom Macroglobulinemia. This ZID regimen will

dexamethasone
cyclophosphamide
fludarabine
cold agglutinin
cytopenia
  • 0 views
  • 24 Jan, 2021
  • 1 location
A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

Response Criteria from the Sixth International Workshop on Waldenstrom's Macroglobulinemia (IWWM) (NCCN 2019), in Chinese participants with relapsed or refractory waldenstrom's macroglobulinemia.

monoclonal antibodies
measurable disease
monoclonal antibody therapy
monoclonal protein
immunoglobulin
  • 1 views
  • 17 Dec, 2020
  • 11 locations
A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022. Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R WM will be evaluated in approximately 44 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.

  • 0 views
  • 24 Jan, 2021
  • 16 locations
Daratumumab Plus Ibrutinib in Patients With Waldenstr m's Macroglobulinemia

This study evaluates the safety and efficacy of daratumumab in combination with ibrutinib in patients with Waldenstrm's macroglobulinemia (WM). The study will evaluate this combination in two

human chorionic gonadotropin
measurable disease
cytopenia
neutrophil count
igm level
  • 1 views
  • 01 Jan, 2021
  • 1 location